Patent ID: 11952426
Assignee: JANSSEN BIOTECH, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating relapsed or refractory multiple myeloma in a human subject in need thereof, comprising administering a therapeutically effective amount of a BCMAxCD3 bispecific antibody to the subject to treat the cancer,
wherein the subject is relapsed or refractory to treatment with at least one prior anti-cancer treatment,
wherein the BCMAxCD3 bispecific antibody comprises a BCMA binding domain comprising a heavy chain variable region (VH) having the amino acid sequence of SEQ ID NO: 10 and a light chain variable region (VL) having the amino acid sequence of SEQ ID NO: 11, and a CD3 binding domain comprising a VH having the amino acid sequence of SEQ ID NO: 20 and a VL having the amino acid sequence of SEQ ID NO: 21,
wherein the BCMAxCD3 bispecific antibody is administered subcutaneously at a dose of about 1500 μg/kg weekly, and
wherein the method is effective in treating the multiple myeloma.